1
|
Schifani E, Giannetti D, Castracani C, Spotti FA, Mori A, Grasso DA. Fight and rescue or give up and flee? Behavioural responses of different ant species tending the mutualist walnut aphid Panaphis juglandis to native and exotic lady beetles. Bull Entomol Res 2023; 113:808-813. [PMID: 37855130 DOI: 10.1017/s0007485323000500] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2023]
Abstract
Mutualism between ants and honeydew-producing hemipterans is a highly successful evolutionary innovation that attains the status of ecological keystone across many terrestrial ecosystems, involving a multitude of actors through direct or cascading effects. In these relationships, ants often protect their hemipteran partners against their arthropod natural enemies, sometimes interfering with the biological control of pest species. However, the dynamics of these interactions are highly variable based on the specific identity of all the actors involved, and baseline data remain scarce. We performed a field experiment exposing colonies of the walnut aphid Panaphis juglandis attended by five European ant species (Camponotus piceus, Ca. vagus, Crematogaster scutellaris, Dolichoderus quadripunctatus, Lasius emarginatus) to a native and an exotic lady beetle (Adalia bipunctata and Harmonia axyridis), documenting the behavioural interactions between these insects and the performance of ants in the protection of the aphids. Our results reveal a significant behavioural diversity among the ant species involved, with D. quadripunctatus and L. emarginatus being the most aggressive and having the best performance as aphid defenders, and Ca. piceus being least effective and often fleeing away. Cr. scutellaris displayed a rare rescue behaviour attempting to pull away the aphids that the lady beetles grabbed. On the other hand, behavioural responses to A. bipunctata and H. axyridis were similar. Further investigations are needed to understand the eco-ethological implications of these differences, while a better understanding of ant behavioural diversity may help refine biological control strategies.
Collapse
Affiliation(s)
- Enrico Schifani
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - Daniele Giannetti
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - Cristina Castracani
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - Fiorenza A Spotti
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - Alessandra Mori
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - Donato A Grasso
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| |
Collapse
|
2
|
Schifani E, Giannetti D, Castracani C, Spotti FA, Mori A, Grasso DA. Fight and rescue or give up and flee? Behavioural responses of different ant species tending the mutualist walnut aphid Panaphis juglandis to native and exotic lady beetles - CORRIGENDUM. Bull Entomol Res 2023; 113:858. [PMID: 38050419 DOI: 10.1017/s000748532300055x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/06/2023]
|
3
|
Iwata A, Kado S, Murakumo M, Shikama T, Motojima G, Mori A, Feng C, Okada H, Minami T, Ohshima S, Kobayashi S, Ishizawa A, Nakamura Y, Konoshima S, Mizuuchi T, Nagasaki K. Measurement of Pa α line from pellet ablation cloud in Heliotron J. Rev Sci Instrum 2022; 93:113537. [PMID: 36461543 DOI: 10.1063/5.0101885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 10/10/2022] [Indexed: 06/17/2023]
Abstract
The Paα line (1875.13 nm) in the near-infrared (NIR) region was evaluated to apply Stark broadening of the line spectrum to the electron density measurement of the small-pellet ablation cloud in Heliotron J, a medium-sized helical-axis heliotron device. Paα is three-to-four times broader than the visible Hβ line (486.13 nm) for the same electron density. Using a portable NIR spectrometer, preliminary proof-of-concept experiments determined the marginal density, below which the broadening was undetectable. The lower detection density limit can be decreased using a narrower entrance slit or a denser grating.
Collapse
Affiliation(s)
- A Iwata
- Graduate School of Energy Science, Kyoto University, Kyoto, Japan
| | - S Kado
- Institute of Advanced Energy, Kyoto University, Kyoto, Japan
| | - M Murakumo
- Graduate School of Engineering, Kyoto University, Kyoto, Japan
| | - T Shikama
- Graduate School of Engineering, Kyoto University, Kyoto, Japan
| | - G Motojima
- National Institute for Fusion Science, Gifu, Japan
| | - A Mori
- Graduate School of Energy Science, Kyoto University, Kyoto, Japan
| | - C Feng
- Graduate School of Energy Science, Kyoto University, Kyoto, Japan
| | - H Okada
- Institute of Advanced Energy, Kyoto University, Kyoto, Japan
| | - T Minami
- Institute of Advanced Energy, Kyoto University, Kyoto, Japan
| | - S Ohshima
- Institute of Advanced Energy, Kyoto University, Kyoto, Japan
| | - S Kobayashi
- Institute of Advanced Energy, Kyoto University, Kyoto, Japan
| | - A Ishizawa
- Graduate School of Energy Science, Kyoto University, Kyoto, Japan
| | - Y Nakamura
- Graduate School of Energy Science, Kyoto University, Kyoto, Japan
| | - S Konoshima
- Institute of Advanced Energy, Kyoto University, Kyoto, Japan
| | - T Mizuuchi
- Institute of Advanced Energy, Kyoto University, Kyoto, Japan
| | - K Nagasaki
- Institute of Advanced Energy, Kyoto University, Kyoto, Japan
| |
Collapse
|
4
|
Mori A, Onozawa M, Tsukamoto S, Ishio T, Yokoyama E, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T. P559: HUMORAL RESPONSE TO MRNA-BASED COVID-19 VACCINE IN PATIENTS WITH MYELOID MALIGNANCIES. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000845124.08444.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
5
|
Onozawa E, Goto A, Oda H, Seki S, Sako T, Mori A. Comparison of the effects of two commercially available prescription diet regimens on the fecal microbiomes of client-owned healthy pet dogs. Pol J Vet Sci 2022; 25:93-101. [PMID: 35575869 DOI: 10.24425/pjvs.2022.140845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
In the present study, we used next-generation sequencing to investigate the impacts of two commercially available prescription diet regimens on the fecal microbiomes of eleven client-owned healthy pet dogs. We tested an anallergenic diet on 6 dogs and a low-fat diet on 5 dogs. Before starting the study, each dog was fed a different commercial diet over 5 weeks. After collecting pre-diet fecal samples, the anallergenic or low-fat diet was administered for 5 weeks. We then collected fecal samples and compared the pre- and post-diet fecal microbiomes. In the dogs on the anallergenic diet, we found significantly decreased proportions of Bacteroides, Ruminococcaceae, and Fusobacteriaceae, belonging to the phyla Bacteroidetes, Firmicutes, and Fusobacteria, respectively. The proportion of the genus Streptococcus belonging to the phylum Firmicutes was significantly increased upon administering the anallergenic diet. In the dogs on the low-fat diet, although the phyla Actinobacteria and Bacteroidetes tended to increase (p=0.116) and decrease (p=0.147) relative to the pre-diet levels, respectively, there were no significant differences in the proportions of any phylum between the pre- and post-diet fecal microbiomes. The anallergenic diet induced a significantly lower diversity index value than that found in the pre-diet period. Principal coordinate analysis based on unweighted UniFrac distance matrices revealed separation between the pre- and post-diet microbiomes in the dogs on the anallergenic diet. These results suggest that, even in pet dogs kept indoors in different living environments, unification of the diet induces apparent changes in the fecal microbiome.
Collapse
Affiliation(s)
- E Onozawa
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan, Musashino, Tokyo 180-8602, Japan
| | - A Goto
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan, Musashino, Tokyo 180-8602, Japan
| | - H Oda
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan, Musashino, Tokyo 180-8602, Japan
| | - S Seki
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan, Musashino, Tokyo 180-8602, Japan
| | - T Sako
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan, Musashino, Tokyo 180-8602, Japan
| | - A Mori
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan, Musashino, Tokyo 180-8602, Japan
| |
Collapse
|
6
|
Giannetti D, Schifani E, Reggiani R, Mazzoni E, Reguzzi MC, Castracani C, Spotti FA, Giardina B, Mori A, Grasso DA. Do It by Yourself: Larval Locomotion in the Black Soldier Fly Hermetia illucens, with a Novel “Self-Harvesting” Method to Separate Prepupae. Insects 2022; 13:insects13020127. [PMID: 35206701 PMCID: PMC8879302 DOI: 10.3390/insects13020127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 01/20/2022] [Accepted: 01/22/2022] [Indexed: 11/17/2022]
Abstract
Simple Summary The black soldier fly Hermetia illucens is a widespread species of fly of American origins, which is increasingly used to develop sustainable waste recycling processes as it is able to develop by consuming a wide variety of wastes as food, while both its body and the residuals of its feeding activity can be re-used in a variety of processes. However, many aspects of its larval biology remain unknown. Among these, there is larval movement and its variation in response to external stimuli and environmental conditions. Larvae of the black soldier fly eventually reach the prepupal stage, during which they stop feeding and seek a shelter to pupate. Sorting prepupae from the younger larvae and feeding substratum can be important in rearing processes, since they are used to obtain adults but are also particularly rich in protein and lipids. We focused our study on behavioural differences between prepupae and younger larvae, describing tonic immobility as an anti-predatory response of both, but also their very different ways of locomotion and reactions to stress. Finally, we developed a practical system to exploit these differences, inducing prepupae to move away from the substratum and other larvae to be efficiently collected. Abstract The neotropical insect Hermetia illucens has become a cosmopolite species, and it is considered a highly promising insect in circular and sustainable economic processes. Being able to feed on a wide variety of organic substrates, it represents a source of lipids and proteins for many uses and produces recyclable waste. We investigated the characteristics and differences in the poorly-known locomotory behaviour of larvae of different instars, paying particular attention to the unique characteristics of the prepupal stage, key to farming and industrial processes. Moreover, we attempted to develop a “self-harvesting” system relying on the behavioural traits of prepupae to obtain their separation from younger larvae under rearing condition with minimum effort. Prepupae differ from younger larvae in their response to physical disturbance in the form of tonic immobility and significantly differ in their locomotory movements. Both prepupae and younger larvae reacted similarly to heat or light-induced stress, but low light and high moisture induced only prepupae to migrate away, which resulted in the development of a highly efficient separation methodology. The new data on the behaviour of H. illucens not only shed new light on some unexplored aspects of its biology, but also led to develop an inexpensive self-harvesting system that can be implemented in small-scale and industrial farming.
Collapse
Affiliation(s)
- Daniele Giannetti
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (E.S.); (C.C.); (F.A.S.); (B.G.); (A.M.); (D.A.G.)
- Correspondence:
| | - Enrico Schifani
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (E.S.); (C.C.); (F.A.S.); (B.G.); (A.M.); (D.A.G.)
| | - Roberto Reggiani
- Azienda Agraria Sperimentale Stuard, Strada Madonna dell’Aiuto, 7/a, San Pancrazio, 43126 Parma, Italy;
| | - Emanuele Mazzoni
- Department of Sustainable Crop Production, Section Sustainable Crop and Food Protection, Università Cattolica del Sacro Cuore, 29122 Piacenza, Italy; (E.M.); (M.C.R.)
| | - Maria Cristina Reguzzi
- Department of Sustainable Crop Production, Section Sustainable Crop and Food Protection, Università Cattolica del Sacro Cuore, 29122 Piacenza, Italy; (E.M.); (M.C.R.)
| | - Cristina Castracani
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (E.S.); (C.C.); (F.A.S.); (B.G.); (A.M.); (D.A.G.)
| | - Fiorenza A. Spotti
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (E.S.); (C.C.); (F.A.S.); (B.G.); (A.M.); (D.A.G.)
| | - Beatrice Giardina
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (E.S.); (C.C.); (F.A.S.); (B.G.); (A.M.); (D.A.G.)
| | - Alessandra Mori
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (E.S.); (C.C.); (F.A.S.); (B.G.); (A.M.); (D.A.G.)
| | - Donato A. Grasso
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (E.S.); (C.C.); (F.A.S.); (B.G.); (A.M.); (D.A.G.)
| |
Collapse
|
7
|
Giannetti D, Schifani E, Castracani C, Spotti FA, Mori A, Grasso DA. Unlike rolling stones: not every Myrmecina species actively rolls away from danger (Hymenoptera, Formicidae). The European Zoological Journal 2021. [DOI: 10.1080/24750263.2021.2011967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- D. Giannetti
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - E. Schifani
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - C. Castracani
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - F. A. Spotti
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - A. Mori
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - D. A. Grasso
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| |
Collapse
|
8
|
Ito S, Erami K, Muratani S, Mori A, Ichikawa S, Yoshino K, Fujimoto H, Lin L, Fallacara D, J. Perry M. Mathematical modeling approaches for quantitative adverse outcome pathway: proof of concept for the integration of key events and key event relationships. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00413-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Mori A, Kaku Y, Dainichi T. Erythema punctatum Higuchi: reconsidering its relationship with adrenergic urticaria and eruptive pseudoangiomatosis. J Eur Acad Dermatol Venereol 2021; 35:e792-e793. [PMID: 34171183 DOI: 10.1111/jdv.17474] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 06/18/2021] [Indexed: 11/28/2022]
Affiliation(s)
- A Mori
- School of Medicine, Kagawa University Faculty of Medicine, Kagawa, Japan
| | - Y Kaku
- Department of Dermatology, Kagawa University Faculty of Medicine, Kagawa, Japan
| | - T Dainichi
- Department of Dermatology, Kagawa University Faculty of Medicine, Kagawa, Japan
| |
Collapse
|
10
|
|
11
|
Miyamoto M, Miyoshi T, Osawa K, Mori A, Oka T, Ito H. Efficacy of early intravenous landiolol, an ultrashort-acting beta-blocker on infarct size and its safety in patients with myocardial infarction undergoing primary PCI: a randomized, controlled study. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Previous clinical studies showed that early intravenous metoprolol before reperfusion in patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI reduced infarct size. However, intravenous beta-blockers in acute phase of STEMI can be associated with adverse effects such as cardiogenic shock and atrioventricular block. Landiolol is an ultrashort-acting beta-blocker with a half-life of 3 min that is eight times more cardioselective than esmolol.
Purpose
We evaluate the efficacy of intravenous infusion of landiolol on infarct size and its safety in STEMI patients undergoing primary PCI.
Methods
This study is a multicenter randomized control trial. A total of 47 patients with Killip class II or less STEMI undergoing PCI within 12 hours of symptoms onset were randomized to receive intravenous landiolol (n=23) or not (control, n=24). Patients allocated to landiolol group delivered an intravenous continuous dose of 3μg/min/kg before reperfusion and then continued until a total dose of 50mg. All patients started oral metoprolol or carvedilol within 12 hours. The primary end point was myocardial salvage index (MSI) on magnetic resonance imaging performed 5 to 7 days after PCI. MSI was defined as the difference between the area at risk and the area of necrosis analyzed using a commercial software.
Results
Magnetic resonance imaging was performed in 35 patients (17 patients in landiolol group and 18 patients in the control group), and ischemia duration time was 229 minutes in the landiolol group and the 242 minutes in control. In adjusting for confounding variables, the areas of myocardium at risk were not difference in both groups (54.4g in the landiolol group, and 46.8g in the control group; p=0.31). However, MSI in the landiolol group was significantly reduced than that in the control group (36.8% and 57.0%; p<0.001).
In both group blood pressure was not difference in recruitment (142mmHg in landiolol group, and 144 in control) and starting PCI (163mmHg in landiolol group, and 165 in control). Regarding safety, the composite of death, malignant ventricular arrhythmia, cardiogenic shock, and atrioventricular block at 24 hours did not differ between the landiolol and the control groups (8.7% and 8.3%, respectively, p=0.93).
Conclusion
Early intravenous landiolol before starting primary PCI reduced infarct size in STEMI patients without significant hemodynamic adverse effects.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M Miyamoto
- Okayama University Hospital, Department of Cardiovascular Therapeutics, Okayama, Japan
| | - T Miyoshi
- Okayama University Hospital, Department of Cardiovascular Therapeutics, Okayama, Japan
| | - K Osawa
- Japanese Red Cross Okayama Hospital, Cardiology, Okayama, Japan
| | - A Mori
- Kagawa Rosai Hospital, Cardiology, Kagawa, Japan
| | - T Oka
- Tsuyama central Hospital, Cardiology, Okayama, Japan
| | - H Ito
- Okayama University Hospital, Department of Cardiovascular Therapeutics, Okayama, Japan
| |
Collapse
|
12
|
Castracani C, Spotti FA, Schifani E, Giannetti D, Ghizzoni M, Grasso DA, Mori A. Public Engagement Provides First Insights on Po Plain Ant Communities and Reveals the Ubiquity of the Cryptic Species Tetramorium immigrans (Hymenoptera, Formicidae). Insects 2020; 11:insects11100678. [PMID: 33036330 PMCID: PMC7601173 DOI: 10.3390/insects11100678] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Revised: 10/02/2020] [Accepted: 10/02/2020] [Indexed: 11/25/2022]
Abstract
Simple Summary Public involvement in biodiversity research in the form of Citizen Science is a powerful tool to improve our understanding of the natural world, and it is especially suitable for the study of heavily populated environments. Ants’ ubiquity and diversity, their role as ecological bioindicators, and the fact that most species can easily be sampled makes them ideal candidates for this kind of studies. In the framework of the international School of Ants citizen science project, we joined the “BioBlitz Lombardia” in which citizens are invited to collect biodiversity data on several parks from Lombardy (Po Plain, Italy). As a result, we recorded 30 ant species and obtained a first characterization of the region’s ant assemblages. We studied their patterns of variation in relation with the ecological difference between the studies sites, which ranged from urban to subalpine areas. In addition, we detected the presence of a cryptic species (Tetramorium immigrans) whose distribution and identity were only recently clarified. It likely represents an under-recorded introduced species in the region. Advantages and critical aspects of using CS methodology for the study of biodiversity are discussed in light of our experience. Abstract Ants are considered a useful model for biodiversity monitoring and several of their characteristics make them promising for citizen science (CS) projects. Involving a wide range of public figures into collecting valuable data on the effect of human impact on ant biodiversity, the School of Ants (SoA) project represents one of the very few attempts to explore the potential of these insects in CS. Through the collaboration with the “BioBlitz Lombardia” project, we tested the SoA protocol on 12 Northern Italy parks, ranging from urban green to subalpine protected sites. As a result, we obtained some of the very first quantitative data characterizing the ants of this region, recording 30 species and highlighting some interesting ecological patterns. These data revealed the ubiquitous presence of the recently taxonomically defined cryptic species Tetramorium immigrans, which appears to be probably introduced in the region. We also discuss advantages and criticisms encountered applying the SoA protocol, originally intended for schools, to new categories of volunteers, from BioBlitz participants to park operators, suggesting best practices based on our experience.
Collapse
|
13
|
Takahashi M, Shimokawa T, Ko J, Takeshima T, Yamashita H, Kajimoto Y, Mori A, Ito H. Efficacy and safety of istradefylline in Parkinson's disease patients with postural abnormality: results from a multicenter open-label study in Japan. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Truong D, Hattori N, Isaacson S, Rascol O, Mori A, Toyama K, Parno J, Salzman P, Ristuccia R, Stocchi F. Effect of baseline dyskinesia on safety and efficacy of istradefylline, an A2A receptor antagonist, in Parkinson's disease: 8-study pooled analysis. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Grasso DA, Giannetti D, Castracani C, Spotti FA, Mori A. Rolling away: a novel context-dependent escape behaviour discovered in ants. Sci Rep 2020; 10:3784. [PMID: 32123182 PMCID: PMC7051971 DOI: 10.1038/s41598-020-59954-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 01/17/2020] [Indexed: 11/09/2022] Open
Abstract
For animals facing dangers, the best option to optimize costs and benefits of defence sometimes may be avoidance. Here we report the discovery of a peculiar strategy adopted by Myrmecina graminicola, a cryptic ant living in forest floor. Experiments showed that when disturbed these ants respond with immobility. However, upon perceiving disturbance but under specific inclinations of the substrate, they shift to an active escaping strategy: rolling away. This is a context-dependent behaviour adopted only in appropriate circumstances. During rolling, the ants assume a ball-like shape using antennae and hind legs to obtain an active movement along a stable trajectory. Finally, we assessed the adaptive value of this strategy measuring its effectiveness in defence against enemies. This is the first example of locomotion by rolling discovered in ants and one of the very few among animals, offering opportunities for multidisciplinary research on the adaptations and biomechanics underlying it.
Collapse
Affiliation(s)
- Donato A Grasso
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Viale delle Scienze11/a, 43124, Parma, Italy.
| | - Daniele Giannetti
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Viale delle Scienze11/a, 43124, Parma, Italy
| | - Cristina Castracani
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Viale delle Scienze11/a, 43124, Parma, Italy
| | - Fiorenza A Spotti
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Viale delle Scienze11/a, 43124, Parma, Italy
| | - Alessandra Mori
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Viale delle Scienze11/a, 43124, Parma, Italy
| |
Collapse
|
16
|
Schifani E, Castracani C, Giannetti D, Spotti FA, Reggiani R, Leonardi S, Mori A, Grasso DA. New Tools for Conservation Biological Control: Testing Ant-Attracting Artificial Nectaries to Employ Ants as Plant Defenders. Insects 2020; 11:insects11020129. [PMID: 32079350 PMCID: PMC7074267 DOI: 10.3390/insects11020129] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Revised: 02/11/2020] [Accepted: 02/13/2020] [Indexed: 01/29/2023]
Abstract
Knowledge of the role of ants in many agroecosystems is relatively scarce, and in temperate regions the possibility to exploit ants as biocontrol agents for crop protection is still largely unexplored. Drawing inspiration from mutualistic ant–plant relationships mediated by extrafloral nectaries (EFNs), we tested the use of artificial nectaries (ANs) in order to increase ant activity on pear trees and to evaluate the effects on the arthropods, plant health and fruit production. While EFNs secrete a complex solution mainly composed of sugars and amino acids, ANs were filled with water and sucrose only. The results suggest that ANs can be used as manipulative instruments to increase ant activity over long periods of time. High ant activity was significantly linked to lower incidence of the pathogen fungus Venturia pyrina (pear scab) on pear leaves, and of the presence of Cydia pomonella (codling moth) caterpillars on pear fruit production. These results further encourage exploring underrated possibilities in the development of new tools for conservation biological control (CBC).
Collapse
Affiliation(s)
- Enrico Schifani
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (D.G.); (F.A.S.); (S.L.); (A.M.); (D.A.G.)
- Correspondence: (E.S.); (C.C.)
| | - Cristina Castracani
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (D.G.); (F.A.S.); (S.L.); (A.M.); (D.A.G.)
- Correspondence: (E.S.); (C.C.)
| | - Daniele Giannetti
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (D.G.); (F.A.S.); (S.L.); (A.M.); (D.A.G.)
| | - Fiorenza Augusta Spotti
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (D.G.); (F.A.S.); (S.L.); (A.M.); (D.A.G.)
| | - Roberto Reggiani
- Azienda Agraria Sperimentale Stuard, Strada Madonna dell’Aiuto, 7/a, 43126 San Pancrazio, Parma, Italy;
| | - Stefano Leonardi
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (D.G.); (F.A.S.); (S.L.); (A.M.); (D.A.G.)
| | - Alessandra Mori
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (D.G.); (F.A.S.); (S.L.); (A.M.); (D.A.G.)
| | - Donato Antonio Grasso
- Department of Chemistry, Life Sciences & Environmental Sustainability, University of Parma, Parco Area delle Scienze, 11/a, 43124 Parma, Italy; (D.G.); (F.A.S.); (S.L.); (A.M.); (D.A.G.)
| |
Collapse
|
17
|
Fukunaga S, Mori A, Ohuchi A, Yoshioka S, Akiba J, Mistuyama K, Tsuruta O, Torimura T. Gastrointestinal: Abdominal pain, diarrhea, and bloody stools in a patient treated for renal cell carcinoma with sunitinib. J Gastroenterol Hepatol 2020; 35:10. [PMID: 31352682 DOI: 10.1111/jgh.14742] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 05/19/2019] [Accepted: 05/22/2019] [Indexed: 12/09/2022]
Affiliation(s)
- S Fukunaga
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan
| | - A Mori
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan
| | - A Ohuchi
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan
| | - S Yoshioka
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan
| | - J Akiba
- Division of Gastroenterology, Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan
| | - K Mistuyama
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan
| | - O Tsuruta
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan
| | - T Torimura
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan
| |
Collapse
|
18
|
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol 2019; 29:888-894. [PMID: 29360932 PMCID: PMC5913649 DOI: 10.1093/annonc/mdy012] [Citation(s) in RCA: 90] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Patient-reported outcomes are integral in benefit-risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone). Patients and methods Treatment-naïve postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) MBC were randomized 2 : 1 to palbociclib plus letrozole (n = 444) or placebo plus letrozole (n = 222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 2 and 3, and day 1 of every other cycle from cycle 5 using the Functional Assessment of Cancer Therapy (FACT)-Breast and EuroQOL 5 dimensions (EQ-5D) questionnaires. Results As of 26 February 2016, the median duration of follow-up was 23 months. Baseline scores were comparable between the two treatment arms. No significant between-arm differences were observed in change from baseline in FACT-Breast Total, FACT-General Total, or EQ-5D scores. Significantly greater improvement in pain scores was observed in the palbociclib plus letrozole arm (-0.256 versus -0.098; P = 0.0183). In both arms, deterioration of FACT-Breast Total score was significantly delayed in patients without progression versus those with progression and patients with partial or complete response versus those without. No significant difference was observed in FACT-Breast and EQ-5D index scores in patients with and without neutropenia. Conclusions Overall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-naïve postmenopausal patients with ER+/HER2- MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients without progression versus those who progressed and in patients with an objective response versus non-responders. ClinicalTrials.gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427).
Collapse
Affiliation(s)
- H S Rugo
- Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.
| | - V Diéras
- Department of Medical Oncology, Institut Curie, Paris, France
| | - K A Gelmon
- Department of Medical Oncology, British Columbia Cancer Agency-Vancouver Centre, Vancouver, Canada
| | - R S Finn
- Division of Hematology/Oncology, University of California, Los Angeles, USA
| | - D J Slamon
- Division of Hematology/Oncology, University of California, Los Angeles, USA
| | - M Martin
- Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, GEICAM, Universidad Complutense, Madrid, Spain
| | - P Neven
- Department of Oncology, Universitair Ziekenhuis Leuven-Campus Gasthuisberg, Leuven, Belgium
| | - Y Shparyk
- Department of Chemotherapy, Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine
| | - A Mori
- Global Product Developmen, Clinical, Pfizer s.r.l., Milan, Italy
| | - D R Lu
- Global Product Developmen, Statistics, Pfizer Inc., La Jolla, USA
| | | | | | - S Iyer
- Global Outcomes and Evidence, Pfizer Inc., New York, USA
| | - S Johnston
- Department of Medical Oncology, The Royal Marsden NHS Foundation, London, UK
| | - J Ettl
- Department of Obstetrics and Gynecology, Frauenklinik und Poliklinik Klinikum Rechts der Isar, Technische Universität München, München, Germany
| | - N Harbeck
- Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), München, Germany
| |
Collapse
|
19
|
Maruyama N, Mori A, Shono S, Oda H, Sako T. Evaluation of changes in periodontal bacteria in healthy dogs over 6 months using quantitative real-time PCR. Pol J Vet Sci 2019; 21:127-132. [PMID: 29623999 DOI: 10.24425/119030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Porphyromonas gulae, Tannerella forsythia and Campylobacter rectus are considered dominant periodontal pathogens in dogs. Recently, quantitative real-time PCR (qRT-PCR) methods have been used for absolute quantitative determination of oral bacterial counts. The purpose of the present study was to establish a standardized qRT-PCR procedure to quantify bacterial counts of the three target periodontal bacteria (P. gulae, T. forsythia and C. rectus). Copy numbers of the three target periodontal bacteria were evaluated in 26 healthy dogs. Then, changes in bacterial counts of the three target periodontal bacteria were evaluated for 24 weeks in 7 healthy dogs after periodontal scaling. Analytical evaluation of each self-designed primer indicated acceptable analytical imprecision. All 26 healthy dogs were found to be positive for P. gulae, T. forsythia and C. rectus. Median total bacterial counts (copies/ng) of each target genes were 385.612 for P. gulae, 25.109 for T. forsythia and 5.771 for C. rectus. Significant differences were observed between the copy numbers of the three target periodontal bacteria. Periodontal scaling reduced median copy numbers of the three target periodontal bacteria in 7 healthy dogs. However, after periodontal scaling, copy numbers of all three periodontal bacteria significantly increased over time (p<0.05, Kruskal-Wallis test) (24 weeks). In conclusion, our results demonstrated that qRT-PCR can accurately measure periodontal bacteria in dogs. Furthermore, the present study has revealed that qRT-PCR method can be considered as a new objective evaluation system for canine periodontal disease.
Collapse
Affiliation(s)
- N Maruyama
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan
| | - A Mori
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan
| | - S Shono
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan
| | - H Oda
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan
| | - T Sako
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan
| |
Collapse
|
20
|
Okuzumi A, Hatano T, Kamagata K, Hori M, Mori A, Oji Y, Taniguchi D, Daida K, Shimo Y, Yanagisawa N, Nojiri S, Aoki S, Hattori N. Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease? Eur J Neurol 2019; 26:1408-1416. [PMID: 31136060 PMCID: PMC6851628 DOI: 10.1111/ene.14009] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 05/23/2019] [Indexed: 01/10/2023]
Abstract
Background and purpose Whether the neuromelanin‐positive substantia nigra pars compacta area (NM‐SNc) on neuromelanin magnetic resonance imaging (NM‐MRI) and the specific binding ratio (SBR) on 123I‐N‐v‐fluoropropyl‐2b‐carbomethoxy3b‐(4‐iodophenyl)nortropane single photon emission computed tomography (DaT‐SPECT) can be correlated with motor fluctuations (MFs) in advanced Parkinson's disease (PD) was investigated. Methods Thirty‐five PD patients (60 ± 13 years) and 23 healthy individuals as controls (59 ± 19 years) were enrolled. The relationships between NM‐MRI and DaT‐SPECT were prospectively examined in two subgroups divided according to the presence or absence of MFs. Multivariate analysis was performed using the Cox proportional hazard model to screen for association factors. Results The NM‐SNc size was correlated with the SBR (Spearman's ρ = 0.43, P < 0.05). The NM‐SNc size was significantly reduced in PD with MFs compared with the subgroup without (P < 0.001), whereas the SBR did not significantly differ between the groups. NM‐SNc size was a significant association factor for MFs (hazard ratio 0.94, P = 0.04). In receiver operating characteristic analysis of the factors for MF occurrence, the area under the receiver operating characteristic curve of the NM‐SNc size showed a significant difference of 0.89 (P < 0.05) but no significant difference was found in the SBR. Conclusions NM‐SNc size was significantly correlated with the SBR in PD, but several factors in advanced PD were more closely associated with NM‐SNc size than the SBR. NM‐MRI might reflect the status of advanced PD more accurately than DaT‐SPECT. Therefore, NM‐MRI appears to provide a better marker for discriminating advanced PD than DaT‐SPECT.
Collapse
Affiliation(s)
- A Okuzumi
- Department of Neurology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - T Hatano
- Department of Neurology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - K Kamagata
- Department of Radiology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - M Hori
- Department of Radiology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - A Mori
- Department of Neurology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Y Oji
- Department of Neurology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - D Taniguchi
- Department of Neurology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - K Daida
- Department of Neurology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Y Shimo
- Department of Neurology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.,Department of Research and Therapeutics for Movement Disorders, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - N Yanagisawa
- Medical Technology Innovation Center, Clinical Research and Trial Center, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - S Nojiri
- Medical Technology Innovation Center, Clinical Research and Trial Center, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - S Aoki
- Department of Radiology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - N Hattori
- Department of Neurology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.,Department of Research and Therapeutics for Movement Disorders, Juntendo University Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
21
|
Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol 2019; 29:669-680. [PMID: 29342248 PMCID: PMC5888946 DOI: 10.1093/annonc/mdx797] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) with or without visceral metastases. Patients and methods Pre- and postmenopausal women with disease progression following prior ET (PALOMA-3; N = 521) and postmenopausal women untreated for ABC (PALOMA-2; N = 666) were randomized 2 : 1 to ET (fulvestrant or letrozole, respectively) plus palbociclib or placebo. Progression-free survival (PFS), safety, and patient-reported quality of life (QoL) were evaluated by prior treatment and visceral involvement. Results Visceral metastases incidence was higher in patients with prior resistance to ET (58.3%, PALOMA-3) than in patients naive to ET in the ABC setting (48.6%, PALOMA-2). In patients with prior resistance to ET and visceral metastases, median PFS (mPFS) was 9.2 months with palbociclib plus fulvestrant versus 3.4 months with placebo plus fulvestrant [hazard ratio (HR), 0.47; 95% confidence interval (CI), 0.35–0.61], and objective response rate (ORR) was 28.0% versus 6.7%, respectively. In patients with nonvisceral metastases, mPFS was 16.6 versus 7.3 months, HR 0.53; 95% CI 0.36–0.77. In patients with visceral disease and naive to ET in the advanced disease setting, mPFS was 19.3 months with palbociclib plus letrozole versus 12.9 months with placebo plus letrozole (HR 0.63; 95% CI 0.47–0.85); ORR was 55.1% versus 40.0%; in patients with nonvisceral disease, mPFS was not reached with palbociclib plus letrozole versus 16.8 months with placebo plus letrozole (HR 0.50; 95% CI 0.36–0.70). In patients with prior resistance to ET with visceral metastases, palbociclib plus fulvestrant significantly delayed deterioration of QoL versus placebo plus fulvestrant, whereas patient-reported QoL was maintained with palbociclib plus letrozole in patients naive to endocrine-based therapy for ABC. Conclusions Palbociclib plus ET prolonged mPFS in patients with visceral metastases, increased ORRs, and in patients previously treated for ABC, delayed QoL deterioration, presenting a standard treatment option among patients with visceral metastases amenable to endocrine-based therapy. Clinical trial registration NCT01942135, NCT01740427
Collapse
Affiliation(s)
- N C Turner
- Toby Robins Breast Cancer Research Centre, Institute of Cancer Research and Royal Marsden Hospital, London, UK.
| | - R S Finn
- Department of Medicine, David Geffen School of Medicine, Los Angeles, USA
| | - M Martin
- Department of Medicine, Hospital Gregorio Marañón, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain
| | - S-A Im
- Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - A DeMichele
- Department of Medicine, University of Pennsylvania, Philadelphia, USA
| | - J Ettl
- Klinik und Poliklinik fuer Frauenheilkunde Klinikum Rechts der Isar, Technische Universitaet Muenchen, Munich, Germany
| | - V Diéras
- Department of Clinical Research, Institut Curie, Paris, France
| | - S Moulder
- Department of Breast Medical Oncology, M.D. Anderson Cancer Center, University of Texas, Houston, USA
| | - O Lipatov
- State Budget Medical Institution Republican Clinical Oncology Dispensary, Ufa, Russia
| | - M Colleoni
- European Institute of Oncology, Milan, Italy
| | - M Cristofanilli
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago
| | - D R Lu
- Pfizer Inc, La Jolla, USA
| | - A Mori
- Pfizer S.r.l, Milan, Italy
| | | | - S Iyer
- Pfizer Inc, New York, USA
| | | | - K A Gelmon
- Department of Medical Oncology, British Columbia Cancer Agency-Vancouver Centre, Vancouver, Canada
| |
Collapse
|
22
|
Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 2019; 174:719-729. [PMID: 30632023 PMCID: PMC6438948 DOI: 10.1007/s10549-018-05125-4] [Citation(s) in RCA: 226] [Impact Index Per Article: 45.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Accepted: 12/26/2018] [Indexed: 11/26/2022]
Abstract
PURPOSE In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up. METHODS In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs). RESULTS After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained. CONCLUSIONS With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.
Collapse
Affiliation(s)
- H S Rugo
- Department of Medicine (Hematology/Oncology), University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, 2nd Floor, San Francisco, CA, 94115, USA.
| | - R S Finn
- Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA
| | - V Diéras
- Department of Medical Oncology, Institut Curie, Paris, France
- Centre Eugène Marquis, Rennes, France
| | - J Ettl
- Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - O Lipatov
- Republican Clinical Oncology Dispensary, State Budget Medical Institution, Ufa, Russia
| | - A A Joy
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - N Harbeck
- Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), Munich, Germany
| | - A Castrellon
- Breast Cancer Center, Memorial Cancer Institute, Hollywood, FL, USA
| | - S Iyer
- Patient and Health Impact, Pfizer Inc, New York, NY, USA
| | - D R Lu
- Clinical Statistics, Pfizer Inc, La Jolla, CA, USA
| | - A Mori
- Global Product Development, Clinical, Pfizer S.r.l, Milan, Italy
| | - E R Gauthier
- Global Product Development, Clinical, Pfizer Inc, San Francisco, CA, USA
| | - C Huang Bartlett
- Global Product Development, Clinical, Pfizer Inc, Collegeville, PA, USA
| | - K A Gelmon
- Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - D J Slamon
- Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA
| |
Collapse
|
23
|
Rugo H, Finn R, Gelmon K, Joy A, Lipatov O, Harbeck N, Castrellon A, Mukai H, Walshe J, Mori A, Gauthier E, Lu D, Bananis E, Martín M, Dieras V. Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Arnan X, Andersen AN, Gibb H, Parr CL, Sanders NJ, Dunn RR, Angulo E, Baccaro FB, Bishop TR, Boulay R, Castracani C, Cerdá X, Toro ID, Delsinne T, Donoso DA, Elten EK, Fayle TM, Fitzpatrick MC, Gómez C, Grasso DA, Grossman BF, Guénard B, Gunawardene N, Heterick B, Hoffmann BD, Janda M, Jenkins CN, Klimes P, Lach L, Laeger T, Leponce M, Lucky A, Majer J, Menke S, Mezger D, Mori A, Moses J, Munyai TC, Paknia O, Pfeiffer M, Philpott SM, Souza JLP, Tista M, Vasconcelos HL, Retana J. Dominance-diversity relationships in ant communities differ with invasion. Glob Chang Biol 2018; 24:4614-4625. [PMID: 29851235 DOI: 10.1111/gcb.14331] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 02/27/2018] [Accepted: 05/16/2018] [Indexed: 06/08/2023]
Abstract
The relationship between levels of dominance and species richness is highly contentious, especially in ant communities. The dominance-impoverishment rule states that high levels of dominance only occur in species-poor communities, but there appear to be many cases of high levels of dominance in highly diverse communities. The extent to which dominant species limit local richness through competitive exclusion remains unclear, but such exclusion appears more apparent for non-native rather than native dominant species. Here we perform the first global analysis of the relationship between behavioral dominance and species richness. We used data from 1,293 local assemblages of ground-dwelling ants distributed across five continents to document the generality of the dominance-impoverishment rule, and to identify the biotic and abiotic conditions under which it does and does not apply. We found that the behavioral dominance-diversity relationship varies greatly, and depends on whether dominant species are native or non-native, whether dominance is considered as occurrence or relative abundance, and on variation in mean annual temperature. There were declines in diversity with increasing dominance in invaded communities, but diversity increased with increasing dominance in native communities. These patterns occur along the global temperature gradient. However, positive and negative relationships are strongest in the hottest sites. We also found that climate regulates the degree of behavioral dominance, but differently from how it shapes species richness. Our findings imply that, despite strong competitive interactions among ants, competitive exclusion is not a major driver of local richness in native ant communities. Although the dominance-impoverishment rule applies to invaded communities, we propose an alternative dominance-diversification rule for native communities.
Collapse
Affiliation(s)
| | - Alan N Andersen
- Research Institute for the Environment and Livelihoods, Charles Darwin University, Casuarina, NT, Australia
| | - Heloise Gibb
- Department of Ecology, Evolution and the Environment, La Trobe University, Melbourne, Vic., Australia
| | - Catherine L Parr
- Department of Earth, Ocean and Ecological Sciences, University of Liverpool, Liverpool, UK
| | - Nathan J Sanders
- Environmental Program, Rubenstein School of Environment and Natural Resources, University of Vermont, Burlington, Vermont
| | - Robert R Dunn
- Department of Applied Ecology, North Carolina State University, Raleigh, North Carolina
| | - Elena Angulo
- Estación Biológica de Doñana CSIC, Sevilla, Spain
| | - Fabricio B Baccaro
- Departamento de Biologia, Universidade Federal do Amazonas, Manaus, Brazil
| | - Tom R Bishop
- Centre for Invasion Biology, Department of Zoology and Entomology, University of Pretoria, Pretoria, South Africa
| | - Raphaël Boulay
- Institute of Insect Biology, University François Rabelais of Tours, Tours, France
| | - Cristina Castracani
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - Xim Cerdá
- Estación Biológica de Doñana CSIC, Sevilla, Spain
| | - Israel Del Toro
- Biology Department, Lawrence University, Appleton, Wisconsin
| | | | - David A Donoso
- Instituto de Ciencias Biológicas, Escuela Politécnicamenk Nacional, Quito, Ecuador
| | - Emilie K Elten
- Center for Macroecology, Evolution, and Climate, Natural History Museum of Denmark, University of Copenhagen, Copenhagen, Denmark
| | - Tom M Fayle
- Biology Centre of the Czech Academy of Sciences, Institute of Entomology, and Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic
| | - Matthew C Fitzpatrick
- Appalachian Lab, University of Maryland Center for Environmental Science, Frostburg, Maryland
| | - Crisanto Gómez
- Department of Environmental Science, University of Girona, Girona, Spain
| | - Donato A Grasso
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - Blair F Grossman
- Department of Ecology, Evolution and the Environment, La Trobe University, Melbourne, Vic., Australia
| | - Benoit Guénard
- School of Biological Sciences, The University of Hong Kong, Hong Kong SAR
| | - Nihara Gunawardene
- Department of Environment and Agriculture, Curtin University, Perth, WA, Australia
| | - Brian Heterick
- Department of Environment and Agriculture, Curtin University, Perth, WA, Australia
| | | | - Milan Janda
- Biology Centre of the Czech Academy of Sciences, Institute of Entomology, and Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic
- National Laboratory for Ecological Analysis and Synthesis (LANASE), ENES, UNAM, Michoacan, Mexico
| | - Clinton N Jenkins
- IPÊ - Instituto de Pesquisas Ecológicas, Nazaré Paulista, SP, Brasil
| | - Petr Klimes
- Biology Centre of the Czech Academy of Sciences, Institute of Entomology, and Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic
- New Guinea Binatang Research Center, Madang, Papua New Guinea
| | - Lori Lach
- College of Science and Engineering, James Cook University, Cairns, Queensland, Australia
| | - Thomas Laeger
- Department of Experimental Diabetology (DIAB), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany
| | - Maurice Leponce
- Biodiversity Monitoring & Assessment, Royal Belgian Institute of Natural Sciences, Brussels, Belgium
| | - Andrea Lucky
- University of Florida Entomology & Nematology Department,, Gainesville, Florida
| | - Jonathan Majer
- School of Biological Sciences, University of WA, Perth, WA, Australia
| | - Sean Menke
- Department of Biology, Lake Forest College, Lake Forest, Illinois
| | - Dirk Mezger
- Department of Biogeography, University of Bayreuth, Bayreuth, Germany
| | - Alessandra Mori
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
| | - Jimmy Moses
- Biology Centre of the Czech Academy of Sciences, Institute of Entomology, and Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic
- New Guinea Binatang Research Center, Madang, Papua New Guinea
| | | | - Omid Paknia
- ITZ, Ecology and Evolution, TiHo Hannover, Hannover, Germany
| | - Martin Pfeiffer
- Department of Biogeography, University of Bayreuth, Bayreuth, Germany
| | - Stacy M Philpott
- Environmental Studies Department, University of California, Santa Cruz, California
| | - Jorge L P Souza
- Science and Technology for Amazonian Resources Graduate Program, Institute of Exact Sciences and Technology (ICET), Itacoatiara, AM, Brazil
- Biodiversity Coordination, National Institute for Amazonian Research (INPA), Manaus, AM, Brazil
| | - Melanie Tista
- Division of Tropical Ecology and Animal Biodiversity, Department of Botany and Biodiversity Research, University of Vienna, Vienna, Austria
| | | | - Javier Retana
- CREAF, Cerdanyola del Vallès, Catalunya, Spain
- Univ Autònoma Barcelona, Cerdanyola del Vallès, Catalunya, Spain
| |
Collapse
|
25
|
Dusi V, Pugliese L, Castelletti S, Dagradi F, Crotti L, Mori A, Camporotondo R, Raineri C, Scelsi L, Ghio S, Savastano S, Vicentini A, Rordorf R, Schwartz PJ, De Ferrari GM. P297Cardiac sympathetic denervation: evolving technique, expanding indications. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- V Dusi
- University of Pavia, Department of Molecular Medicine, Pavia, Italy
| | - L Pugliese
- Policlinic Foundation San Matteo IRCCS, Department of Surgery, Pavia, Italy
| | - S Castelletti
- Italian Institute for Auxology IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy
| | - F Dagradi
- Italian Institute for Auxology IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy
| | - L Crotti
- Italian Institute for Auxology IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy
| | - A Mori
- Policlinic Foundation San Matteo IRCCS, Department of Emergency and Urgency, Pavia, Italy
| | - R Camporotondo
- Policlinic Foundation San Matteo IRCCS, Coronary Care Unit and Laboratory for Clinical and Experimental Cardiology, Pavia, Italy
| | - C Raineri
- Policlinic Foundation San Matteo IRCCS, Department of Cardiology, Pavia, Italy
| | - L Scelsi
- Policlinic Foundation San Matteo IRCCS, Department of Cardiology, Pavia, Italy
| | - S Ghio
- Policlinic Foundation San Matteo IRCCS, Department of Cardiology, Pavia, Italy
| | - S Savastano
- Policlinic Foundation San Matteo IRCCS, Department of Cardiology, Pavia, Italy
| | - A Vicentini
- Policlinic Foundation San Matteo IRCCS, Department of Cardiology, Pavia, Italy
| | - R Rordorf
- Policlinic Foundation San Matteo IRCCS, Department of Cardiology, Pavia, Italy
| | - P J Schwartz
- Italian Institute for Auxology IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy
| | - G M De Ferrari
- University of Pavia, Department of Molecular Medicine, Pavia, Italy
| |
Collapse
|
26
|
Kuriyama K, Suzuki M, Kadotani H, Yoshimura A, Yoshinaka H, Yamanaka M, Tsuboi H, Ueda T, Mori A, Kashiwagi K, Yoshida M, Omori T, Kutsumi H, Uchiyama M, Yamada N. 0972 Practical Use Of A Single Channel Sleep EEG For Diagnosis Of Major Depressive Disorder - Multicenter Exploratory Prospective Study (SEEDs) -. Sleep 2018. [DOI: 10.1093/sleep/zsy061.971] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- K Kuriyama
- Department of Psychiatry, Shiga University of Medical Science, Otsu, JAPAN
| | - M Suzuki
- Department of Psychiatry, Nihon University of Medicine, Itabashi, JAPAN
| | - H Kadotani
- Department of Sleep and Behavioral Science, Shiga University of Medical Science, Otsu, JAPAN
| | - A Yoshimura
- Department of Psychiatry, Shiga University of Medical Science, Otsu, JAPAN
| | - H Yoshinaka
- Clinical Research Development Center, University of Medical Science Hospital, Otsu, JAPAN
| | - M Yamanaka
- Clinical Research Development Center, University of Medical Science Hospital, Otsu, JAPAN
| | - H Tsuboi
- Clinical Research Development Center, University of Medical Science Hospital, Otsu, JAPAN
| | - T Ueda
- Clinical Research Development Center, University of Medical Science Hospital, Otsu, JAPAN
| | - A Mori
- Center of Clinical Research, Kobe University Hospital, Kobe, JAPAN
| | | | | | - T Omori
- Center of Clinical Research, Kobe University Hospital, Kobe, JAPAN
| | - H Kutsumi
- Clinical Research Development Center, University of Medical Science Hospital, Otsu, JAPAN
| | - M Uchiyama
- Department of Psychiatry, Nihon University of Medicine, Itabashi, JAPAN
| | - N Yamada
- Department of Psychiatry, Shiga University of Medical Science, Otsu, JAPAN
| |
Collapse
|
27
|
Matsui N, Nodera H, Kuzume D, Iwasa N, Unai Y, Sakai W, Miyazaki Y, Yamazaki H, Osaki Y, Mori A, Furukawa T, Tsukamoto-Miyashiro A, Shimatani Y, Yamasaki M, Izumi Y, Kusunoki S, Arisawa K, Kaji R. Guillain−Barré syndrome in a local area in Japan, 2006-2015: an epidemiological and clinical study of 108 patients. Eur J Neurol 2018; 25:718-724. [DOI: 10.1111/ene.13569] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Accepted: 01/08/2018] [Indexed: 11/30/2022]
Affiliation(s)
- N. Matsui
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - H. Nodera
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - D. Kuzume
- Department of Neurology; Chikamori Hospital; Kochi Japan
| | - N. Iwasa
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - Y. Unai
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - W. Sakai
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - Y. Miyazaki
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - H. Yamazaki
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - Y. Osaki
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - A. Mori
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - T. Furukawa
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - A. Tsukamoto-Miyashiro
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - Y. Shimatani
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - M. Yamasaki
- Department of Neurology; Chikamori Hospital; Kochi Japan
| | - Y. Izumi
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - S. Kusunoki
- Department of Neurology; Kindai University; Faculty of Medicine; Osaka Japan
| | - K. Arisawa
- Department of Preventive Medicine; Institute of Biomedical Sciences; Tokushima University Graduate School; Tokushima Japan
| | - R. Kaji
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| |
Collapse
|
28
|
Harbeck N, Dieras V, Finn R, Gelmon KA, Walshe JM, Shparyk Y, Mori A, Lui DR, Bhattacharyya H, Iyer S, Johnston S, Rugo HS. Abstract P5-19-01: Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-19-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Palbociclib plus letrozole significantly improved progression-free survival (PFS) compared with letrozole plus placebo in treatment-naive postmenopausal patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) in the phase 3 PALOMA-2 trial. Here, we compare patient-reported general health status with extended (max 53 cycles) follow-up (data cut off May31st, 2017) (Pfizer: NCT01740427).
METHODS: PALOMA-2 randomized patients 2:1 to palbociclib + letrozole (n=444) or placebo + letrozole (n=222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 1, 2, and 3, and day 1 of every other cycle from cycle 5 until the end of treatment using the EuroQol 5-Dimension Questionnaire (EQ-5D). The EQ-5D is a standardized measure of health status that consists of a descriptive system comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression rated at 3 levels (no, some, or extreme problems) and a single index score for health status (ranges generally from 0 [dead] to 1 [full health]) calculated using a standard algorithm. In addition, a visual analog scale (VAS) measured self-rated health status from 0 (worst imaginable) to 100 (best imaginable). Repeated measures mixed-effects analyses were performed to compare overall index and VAS scores between treatments, controlling for baseline.
RESULTS: Completion rates at baseline were >95% in each group. The mean (SD) scores at baseline were comparable between palbociclib plus letrozole and letrozole alone for the VAS (71.3 [21.2] vs 72.3 [19.8]) and the EQ-5D index scores (0.70 [0.25]) vs (0.73 [0.21]). Median follow up was 38 months for palbociclib plus letrozole and 37 months for letrozole only. No statistically significant difference in overall change from baseline in general health status was observed between the treatment arms. The proportion of patients reporting the presence of a problem at baseline was similar for palbociclib plus letrozole and letrozole, respectively: mobility (39% vs 39%), self-care (12% vs 12%), usual activities (44% vs 39%), pain (69% vs 65%), and anxiety/depression (54% vs 54%). No statistically significant difference in overall mean EQ-5D index scores (0.73 vs. 0.71) was observed between the treatment arms.
CONCLUSION: Addition of palbociclib to letrozole maintained general health status and EQ-5D index scores in ER+ HER2- advanced/metastatic breast cancer with no statistically significant differences observed compared to letrozole alone.
Citation Format: Harbeck N, Dieras V, Finn R, Gelmon KA, Walshe JM, Shparyk Y, Mori A, Lui DR, Bhattacharyya H, Iyer S, Johnston S, Rugo HS. Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-19-01.
Collapse
Affiliation(s)
- N Harbeck
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - V Dieras
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - R Finn
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - KA Gelmon
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - JM Walshe
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - Y Shparyk
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - A Mori
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - DR Lui
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - H Bhattacharyya
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - S Iyer
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - S Johnston
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - HS Rugo
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| |
Collapse
|
29
|
Rugo HS, Finn RS, Dieras V, Ettl J, Lipatov O, Joy A, Harbeck N, Castrellon A, Lu DR, Mori A, Gauthier ER, Huang C, Gelmon KA, Slamon DJ. Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-03] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Endocrine therapy (ET) has been the primary first-line (1L) therapy for ER+ ABC. In the PALOMA-2 study (NCT01740427), PAL (P)+LET (L) significantly prolonged progression-free survival (PFS; HR=0.58, P<.001) after a median 23 mo follow-up (FU) (Finn et al. NEJM 2016). Here we report more mature PFS overall and in subgroups, with (w/) longer FU. The study is ongoing for overall survival FU.
METHODS: Postmenopausal pts w/ ER+/HER2- ABC and no prior systemic therapy in the ABC setting were randomized 2:1 to P (125 mg/d) + L (2.5 mg QD) or placebo (PBO) + L. Key endpoints: investigator-assessed PFS and safety. Median PFS (mPFS) was estimated (intent-to-treat population).
RESULTS: 666 pts (444, P+L; 222, PBO+L) were enrolled. Arms were well balanced: visceral (48%)/nonvisceral (52%) disease and prior ET (56%)/no prior ET (44%). After a median FU of 38 mo w/ P+L and 37 mo w/ PBO+L, mPFS was 27.6 and 14.5 mo, respectively, in the overall population (HR=0.56, P<.0001; Table).
TABLE. mPFS overall and by relevant subgroupsP+LPBO+LP+L vs PBO+LmPFS, mo (95% CI)mPFS, mo (95% CI)HR (95% CI)P* Overall27.6 (22.4–30.3)14.5 (12.3–17.1)0.56 (0.46–0.69)<.0001 Measurable disease23.7 (19.3–27.6)14.5 (12.3–18.5)0.63 (0.50–0.79)<.0001 Nonmeasurable disease36.2 (27.6?NE)16.5 (8.3–19.6)0.39 (0.25–0.60)<.0001 Visceral19.3 (16.4–24.2)12.3 (8.4–16.4)0.62 (0.47–0.81)<.0005 Nonvisceral35.9 (27.7–NE)17.0 (13.8–24.8)0.50 (0.37–0.67)<.0001 Bone only†36.2 (27.6–NE)11.2 (8.2–22.0)0.41 (0.26–0.63)<.0001 Not bone only24.2 (19.4–27.7)14.5 (12.9–18.5)0.62 (0.50–0.78)<.0001 De novo metastatic27.9 (22.1–33.4)22.0 (13.9–27.4)0.61 (0.44–0.85)<.005 Prior ET24.2 (18.8–27.6)11.2 (8.4–14.5)0.54 (0.42–0.71)<.0001 No prior ET30.3 (24.5–35.7)21.9 (15.9–27.4)0.59 (0.43–0.80)<.0005 Nonvisceral36.2 (27.9–NE)27.6 (19.1–35.6)0.59 (0.38–0.92)<.01 Visceral23.7 (16.8–30.3)13.9 (10.2–22.2)0.55 (0.36–0.85)<.005 Disease sites130.4 (24.8–NE)16.5 (11.0–22.1)0.52 (0.36–0.75)<.0005228.1 (19.4–NE)16.3 (11.0–27.4)0.57 (0.37–0.89)<.01323.7 (19.2–27.6)13.8 (8.8–17.0)0.61 (0.46–0.82)<.0005NE=not estimable. *Not adjusted for multiple analyses; 1-sided P values. †Per tumor site.
All subgroups benefited from addition of P to L. Notably, pts w/ low disease burden (bone only, nonvisceral disease, few disease sites) derived significant PFS benefit, including those w/ both nonvisceral disease and no prior ET (mPFS, 36.2 vs 27.6 mo; HR=0.59, P<.01). Importantly, median time from randomization to start of 2nd subsequent systemic anticancer therapy was 39 vs 29 mo for P+L vs PBO+L (HR=0.72, P<.005). There were no new safety signals w/ longer FU.
CONCLUSIONS: This is the longest FU of a phase 3 study of a cyclin-dependent kinase 4/6 inhibitor for ABC. P+L continues to consistently improve PFS vs PBO+L across all subgroups while toxicity remains manageable; notably P+L delays time to starting 2nd subsequent anticancer therapies by 10 mo. Pts w/ low disease burden or sensitivity to ET alone had PFS >3 y (significant vs PBO+L), demonstrating the clinical benefit of P+ET. These data confirm P+L should be a 1L therapy option for pts w/ HR+/HER2- ABC.
Funding: Pfizer
Citation Format: Rugo HS, Finn RS, Dieras V, Ettl J, Lipatov O, Joy A, Harbeck N, Castrellon A, Lu DR, Mori A, Gauthier ER, Huang C, Gelmon KA, Slamon DJ. Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-03.
Collapse
Affiliation(s)
- HS Rugo
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - RS Finn
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - V Dieras
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - J Ettl
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - O Lipatov
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - A Joy
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - N Harbeck
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - A Castrellon
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - DR Lu
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - A Mori
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - ER Gauthier
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - C Huang
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - KA Gelmon
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| | - DJ Slamon
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Institut Curie and Center Eugene Marquis Rennes, Paris, France; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Republican Clinical Oncology Dispensary, Ufa, Russian Federation; Cross Cancer Institute, University of Alberta, Edmonton, Canada; Brustzentrum der Universität München, Munich, Germany; Memorial Cancer Institute, Pembroke Pines, FL; Pfizer, Inc.; British Columbia Cancer Agency, Canada; David Geffen School of Medicine at UCLA
| |
Collapse
|
30
|
Gelmon KA, Castrellon A, Joy AA, Walshe JM, Ettl J, Mukai H, Park IH, Lu DR, Mori A, Bananis E, Diéras V, Finn RS. Abstract P5-21-25: Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Previous findings from the PALOMA-2 study (N=666) demonstrated the efficacy and safety of PAL+LET as first-line ABC therapy versus placebo (PBO)+LET (Finn et al, NEJM. 2016). This analysis evaluated the efficacy and safety of PAL+LET by geographic region (North America [NA], Europe [EU], and Asia Pacific [AP]; data cutoff: Feb 26, 2016).
METHODS: Women with ER+/HER2– ABC who had not received prior systemic treatment in the advanced setting were randomized 2:1 to PAL (125 mg/d oral [3 wks on, 1 wk off])+LET (2.5 mg once daily) or PBO+LET.
RESULTS: This analysis included 267 patients from NA, 307 from EU, and 92 from AP. At baseline, demographics and disease characteristics generally were similar between regions. In the overall population (Table 1), PAL+LET demonstrated improvements versus PBO+LET in progression-free survival (PFS), objective response rate (ORR), and clinical benefit response rate (CBR). Similarly, PFS was longer and ORR and CBR were higher with PAL+LET versus PBO+LET in NA, EU, and AP subgroups (Table 1). All-grade treatment-emergent adverse events (AEs) (PAL+LET/PBO+LET) occurred in 99%/99% of patients in NA, 98%/92% in EU, and 100%/96% in AP. In the PAL+LET arm, neutropenia (all-grade/grade ≥3) was the most common AE in all regions. The incidence of neutropenia was numerically higher in AP (91%/84%) compared with NA (73%/65%) and EU (81%/62%). Grade 3 or 4 febrile neutropenia occurred in 4 (2%) NA patients, 4 (2%) EU patients, and no AP patients in the PAL+LET arm and in no patients in any of the regions in the PBO+LET arm.
CONCLUSIONS: PAL+LET showed improvement versus PBO+LET in PFS, ORR, and CBR in patients with ER+/HER2- ABC in NA, EU, and AP, with comparable magnitude of benefit between regions. With PAL+LET, neutropenia was the most commonly reported AE in all regions, with a numerically higher incidence reported in AP versus NA or EU; the safety profile was similar to previously reported results in the overall population.
Funding: Pfizer (NCT01740427)
section, copy and paste the following tag, including brackets, where you would like your table to appear
Table 1. PFS, ORR, and CBR Median PFSPFS HRORR,* %CBR,* % (95% CI), mo(95% CI)(95% CI)(95% CI)Overall Population PAL+LET24.8 (22.1-NE)0.58 (0.46-0.72); P<0.00155.3 (49.9-60.7)84.3 (80.0-88.0)PBO+LET14.5 (12.9-17.1) 44.4 (36.9-52.2)70.8 (63.3-77.5)NA PAL+LET24.2 (17.5-NE)0.61 (0.43-0.85)54.3 (45.3-63.2)80.3 (72.3-86.8)PBO+LET13.8 (10.3-22.1) 50.6 (39.1-62.1)67.1 (55.6-77.3)EU PAL+LET24.8 (22.1-NE)0.57 (0.41-0.80)55.6 (47.6-63.5)87.5 (81.4-92.2)PBO+LET16.5 (11.3-19.6) 38.2 (26.7-50.8)73.5 (61.4-83.5)AP PAL+LET22.2 (19.4-25.7)0.49 (0.27-0.87)56.9 (42.2-70.7)84.3 (71.4-93.0)PBO+LET13.9 (7.4-22.0) 41.7 (22.1-63.4)75.0 (53.3-90.2)HR=hazard ratio; NE=not estimable; OR=objective response.*Confirmed OR in patients with measurable disease.
.
Citation Format: Gelmon KA, Castrellon A, Joy AA, Walshe JM, Ettl J, Mukai H, Park IH, Lu DR, Mori A, Bananis E, Diéras V, Finn RS. Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2 [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-25.
Collapse
Affiliation(s)
- KA Gelmon
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - A Castrellon
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - AA Joy
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - JM Walshe
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - J Ettl
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - H Mukai
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - IH Park
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - DR Lu
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - A Mori
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - E Bananis
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - V Diéras
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| | - RS Finn
- British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Cancer Institute, Breast Cancer Center, Pembroke Pines, FL; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Cancer Trials Ireland, Dublin, Ireland; Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, München, Germany; National Cancer Center Hospital East Tokyo, Tokyo, Japan; National Cancer Center, Goyangsi, Korea; Pfizer Inc, La Jolla, CA; Pfizer S.r.l., Milan, Italy; Pfizer Inc, New York, NY; Institut Curie, Paris, France; David Geffen School of Medicine at UCLA, Santa Monica, CA
| |
Collapse
|
31
|
Kuriyama K, Suzuki M, Kadotani H, Yoshinaka H, Yamanaka M, Omori T, Mori A, Tsuboi H, Ueda T, Kashiwagi K, Yoshimura A, Yoshiike T, Takahashi M, Matsuo M, Morita S, Takami M, Fujii Y, Nakabayashi T, Yoshida M, Kutsumi H, Uchiyama M, Yamada N. A research project aimed at developing practical use of sleep EEG for diagnosis of major depressive disorder: multicenter exploratory prospective study. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Takamatsu N, Nodera H, Mori A, Yamazaki H, Izumi Y, Kaji R. Angle-dependent alteration of muscle echo-densities to effectively diagnose myopathic conditions. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Isaacson S, Eggert K, Kumar R, Stocchi F, Mori A, Ohta E, Toyama K, Spence G, Clark G, Cantillon M. Efficacy and safety of istradefylline in moderate to severe Parkinson’s disease: A phase 3, multinational, randomized, double-blind, placebo-controlled trial (i-step study). J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.999] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Mori A, Nodera H, Takamatsu N, Hashiguchi S, Izumi Y, Kaji R. Characteristic involvement of muscle ultrasound in myotonic dystrophy type 1. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Koinuma T, Mori A, Hatano T, Imai Y, Hattori N. Function analysis of c19orf12 by using a model of drosophila. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Diéras V, Harbeck N, Joy A, Gelmon K, Ettl J, Verma S, Lu D, Gauthier E, Schnell P, Mori A, Rugo H, Finn R. PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.054] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Finn R, Gelmon K, Ettl J, Asselah J, Castrellon A, Ruiz Simón A, Joy A, Lu D, Gauthier E, Mori A, Rugo H, Diéras V. Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Dusi V, Tavazzi G, Camporotondo R, Raineri C, Ghio S, Mori A, Vicentini A, Rordorf R, Pugliese L, De Ferrari G. 4988Bilateral cardiac sympathetic denervation for severe electrical storms in structural heart disease: first European experience. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx495.4988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Shiota S, Okamoto Y, Okada G, Takagaki K, Takamura M, Mori A, Yokoyama S, Nishiyama Y, Jinnin R, Hashimoto RI, Yamawaki S. Effects of behavioural activation on the neural basis of other perspective self-referential processing in subthreshold depression: a functional magnetic resonance imaging study. Psychol Med 2017; 47:877-888. [PMID: 27894368 PMCID: PMC5341493 DOI: 10.1017/s0033291716002956] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 10/12/2016] [Accepted: 10/14/2016] [Indexed: 01/01/2023]
Abstract
BACKGROUND It has been demonstrated that negatively distorted self-referential processing, in which individuals evaluate one's own self, is a pathogenic mechanism in subthreshold depression that has a considerable impact on the quality of life and carries an elevated risk of developing major depression. Behavioural activation (BA) is an effective intervention for depression, including subthreshold depression. However, brain mechanisms underlying BA are not fully understood. We sought to examine the effect of BA on neural activation during other perspective self-referential processing in subthreshold depression. METHOD A total of 56 subjects underwent functional magnetic resonance imaging scans during a self-referential task with two viewpoints (self/other) and two emotional valences (positive/negative) on two occasions. Between scans, while the intervention group (n = 27) received BA therapy, the control group (n = 29) did not. RESULTS The intervention group showed improvement in depressive symptoms, increased activation in the dorsal medial prefrontal cortex (dmPFC), and increased reaction times during other perspective self-referential processing for positive words after the intervention. Also, there was a positive correlation between increased activation in the dmPFC and improvement of depressive symptoms. Additionally, there was a positive correlation between improvement of depressive symptoms and increased reaction times. CONCLUSIONS BA increased dmPFC activation during other perspective self-referential processing with improvement of depressive symptoms and increased reaction times which were associated with improvement of self-monitoring function. Our results suggest that BA improved depressive symptoms and objective monitoring function for subthreshold depression.
Collapse
Affiliation(s)
- S. Shiota
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y. Okamoto
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - G. Okada
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - K. Takagaki
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M. Takamura
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - A. Mori
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - S. Yokoyama
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y. Nishiyama
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - R. Jinnin
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - R. I. Hashimoto
- Department of Language Sciences, Graduate School of Humanities, Tokyo Metropolitan University, Tokyo, Japan
- Medical Institute of Developmental Disabilities Research, Showa University, Tokyo, Japan
| | - S. Yamawaki
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
40
|
Brondino N, Fusar-Poli L, Rocchetti M, Besozzi M, Mori A, Fasoli F, Politi P. QTc Interval in psychiatric inpatients: A retrospective study. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionSeveral psychotropic medications (i.e. antipsychotics, antidepressant) have been recently associated with QTc prolongation. Despite literature data report only mild prolongation of QTc following the use of antidepressants or typical antipsychotics, post-marketing studies have clearly evidenced an increased risk of QTc prolongation and potentially lethal arrhythmias (i.e. torsade de pointes) in psychiatric patients.ObjectivesWe aimed to evaluate the prevalence of prolonged QTc and to identify potential predictors influencing QTc in a psychiatric inpatient population.MethodsMedical records of 200 patients admitted to our psychiatric ward between 2007 and 2012 were retrospectively reviewed.ResultsPrevalence of prolonged QTc at admission was very low (0.1%). No significant differences in QTc interval were observed between patients taking or not antipsychotics (P = 0.66), mood stabilizers (P = 0.36), or antidepressants (P = 0.07). A statistically significant difference was observed between patients on depot formulation and patients who were taking oral antipsychotic (P = 0.02). However, the pharmaceutical class of the medications appeared not significant.ConclusionsWe observed a very low rate of QTc prolongation in psychiatric inpatients at admission. Surprisingly we did not find a significant effect of specific medications; however, in our sample intramuscular formulation was associated with lower QTc interval.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
41
|
Simulundu E, Chambaro HM, Sinkala Y, Kajihara M, Ogawa H, Mori A, Ndebe J, Dautu G, Mataa L, Lubaba CH, Simuntala C, Fandamu P, Simuunza M, Pandey GS, Samui KL, Misinzo G, Takada A, Mweene AS. Co-circulation of multiple genotypes of African swine fever viruses among domestic pigs in Zambia (2013-2015). Transbound Emerg Dis 2017; 65:114-122. [PMID: 28299893 DOI: 10.1111/tbed.12635] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Indexed: 11/27/2022]
Abstract
During 2013-2015, several and severe outbreaks of African swine fever (ASF) affected domestic pigs in six provinces of Zambia. Genetic characterization of ASF viruses (ASFVs) using standardized genotyping procedures revealed that genotypes I, II and XIV were associated with these outbreaks. Molecular and epidemiological data suggest that genotype II ASFV (Georgia 2007/1-like) detected in Northern Province of Zambia may have been introduced from neighbouring Tanzania. Also, a genotype II virus detected in Eastern Province of Zambia showed a p54 phylogenetic relationship that was inconsistent with that of p72, underscoring the genetic variability of ASFVs. While it appears genotype II viruses detected in Zambia arose from a domestic pig cycle, genotypes I and XIV possibly emerged from a sylvatic cycle. Overall, this study demonstrates the co-circulation of multiple genotypes of ASFVs, involvement of both the sylvatic and domestic pig cycle in ASF outbreaks in Zambia and possible trans-boundary spread of the disease in south-eastern Africa. Indeed, while there is need for regional or international concerted efforts in the control of ASF, understanding pig marketing practices, pig population dynamics, pig housing and rearing systems and community engagement will be important considerations when designing future prevention and control strategies of this disease in Zambia.
Collapse
Affiliation(s)
- E Simulundu
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia
| | - H M Chambaro
- Department of Veterinary Services, Ministry of Fisheries and Livestock, Lusaka, Zambia
| | - Y Sinkala
- Department of Veterinary Services, Ministry of Fisheries and Livestock, Lusaka, Zambia
| | - M Kajihara
- Division of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan
| | - H Ogawa
- Department of Virology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - A Mori
- Division of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan
| | - J Ndebe
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia
| | - G Dautu
- Department of Veterinary Services, Ministry of Fisheries and Livestock, Lusaka, Zambia
| | - L Mataa
- Department of Veterinary Services, Ministry of Fisheries and Livestock, Lusaka, Zambia
| | - C H Lubaba
- Department of Veterinary Services, Ministry of Fisheries and Livestock, Lusaka, Zambia
| | - C Simuntala
- Department of Veterinary Services, Ministry of Fisheries and Livestock, Lusaka, Zambia
| | - P Fandamu
- Department of Veterinary Services, Ministry of Fisheries and Livestock, Lusaka, Zambia
| | - M Simuunza
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia
| | - G S Pandey
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia
| | - K L Samui
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia
| | - G Misinzo
- Department of Veterinary Microbiology and Parasitology, Sokoine University of Agriculture, Morogoro, Tanzania
| | - A Takada
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia.,Division of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.,Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, Japan
| | - A S Mweene
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia
| |
Collapse
|
42
|
Gibb H, Dunn RR, Sanders NJ, Grossman BF, Photakis M, Abril S, Agosti D, Andersen AN, Angulo E, Armbrecht I, Arnan X, Baccaro FB, Bishop TR, Boulay R, Brühl C, Castracani C, Cerda X, Del Toro I, Delsinne T, Diaz M, Donoso DA, Ellison AM, Enriquez ML, Fayle TM, Feener DH, Fisher BL, Fisher RN, Fitzpatrick MC, Gómez C, Gotelli NJ, Gove A, Grasso DA, Groc S, Guenard B, Gunawardene N, Heterick B, Hoffmann B, Janda M, Jenkins C, Kaspari M, Klimes P, Lach L, Laeger T, Lattke J, Leponce M, Lessard JP, Longino J, Lucky A, Luke SH, Majer J, McGlynn TP, Menke S, Mezger D, Mori A, Moses J, Munyai TC, Pacheco R, Paknia O, Pearce-Duvet J, Pfeiffer M, Philpott SM, Resasco J, Retana J, Silva RR, Sorger MD, Souza J, Suarez A, Tista M, Vasconcelos HL, Vonshak M, Weiser MD, Yates M, Parr CL. A global database of ant species abundances. Ecology 2017; 98:883-884. [DOI: 10.1002/ecy.1682] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Revised: 11/22/2016] [Accepted: 11/29/2016] [Indexed: 11/07/2022]
Affiliation(s)
- Heloise Gibb
- Department of Ecology, Environment and Evolution; La Trobe University; Melbourne 3086 Victoria Australia
| | - Rob R. Dunn
- Department of Applied Ecology; North Carolina State University; Raleigh North Carolina 27695 USA
- Center for Macroecology, Evolution, and Climate; Natural History Museum of Denmark; University of Copenhagen; Universitetsparken 15 DK-2100 Copenhagen Ø Denmark
| | - Nathan J. Sanders
- Center for Macroecology, Evolution, and Climate; Natural History Museum of Denmark; University of Copenhagen; Universitetsparken 15 DK-2100 Copenhagen Ø Denmark
| | - Blair F. Grossman
- Department of Ecology, Environment and Evolution; La Trobe University; Melbourne 3086 Victoria Australia
| | - Manoli Photakis
- Department of Ecology, Environment and Evolution; La Trobe University; Melbourne 3086 Victoria Australia
| | - Silvia Abril
- Department of Environmental Science; University of Girona; Montilivi Campus s/n 17071 Girona Spain
| | - Donat Agosti
- Naturhistorisches Museum Bern; Bernastrasse 15 3005 Bern Switzerland
| | - Alan N. Andersen
- CSIRO Ecosystem Sciences, Tropical Ecosystems Research Centre; PMB 44 Winnellie Northern Territory 0822 Australia
| | - Elena Angulo
- Departamento de Etología y Conservación de la Biodiversidad; Estación Biológica de Doñana; Avenida Americo Vespucio s/n (Isla de la Cartuja) Sevilla 41092 Spain
| | - Inge Armbrecht
- Facultad de Ciencias Naturales y Exactas; Universidad del Valle; Cali Colombia
| | - Xavier Arnan
- Departamento de Botânica; Universidade Federal Pernambuco; Avenida Prof Moraes Rego s/no Cidade Universitária Pernambuco Brazil
| | - Fabricio B. Baccaro
- Departamento de Biologia; Universidade Federal do Amazonas-UFAM; Manaus Amazonas Brazil
| | - Tom R. Bishop
- Department of Earth, Ocean and Ecological Sciences; University of Liverpool; Liverpool L69 3GP United Kingdom
- Department of Zoology and Entomology; Centre for Invasion Biology; University of Pretoria; Pretoria 0002 South Africa
| | - Raphaël Boulay
- Institut de Recherche sur la Biologie de l'Insecte et Département, d'Aménagement du Territoire Université; François Rabelais de Tours; Tours 37200 France
| | - Carsten Brühl
- Institute for Environmental Sciences; University Koblenz-Landau; Fortstraße 7 76829 Landau in der Pfalz Germany
| | - Cristina Castracani
- Department of Life Sciences; University of Parma; Parco Area delle Scienze 11/A Parma 43124 Italy
| | - Xim Cerda
- Departamento de Etología y Conservación de la Biodiversidad; Estación Biológica de Doñana; Avenida Americo Vespucio s/n (Isla de la Cartuja) Sevilla 41092 Spain
| | - Israel Del Toro
- Center for Macroecology, Evolution, and Climate; Natural History Museum of Denmark; University of Copenhagen; Universitetsparken 15 DK-2100 Copenhagen Ø Denmark
| | - Thibaut Delsinne
- Société d'Histoire Naturelle Alcide-d'Orbigny; 57 rue de Gergovie 63170 Aubière France
| | - Mireia Diaz
- Department of Environmental Science; University of Girona; Montilivi Campus s/n 17071 Girona Spain
| | - David A. Donoso
- Instituto de Ciencias Biológicas; Escuela Politécnica Nacional; Avenida Ladrón de Guevara E11253 Quito Ecuador
| | - Aaron M. Ellison
- Harvard Forest; Harvard University; 324 North Main Street Petersham Massachusetts 01366 USA
- Departments of Biology and Environmental Conservation; University of Massachusetts; Morrill Science Center and Holdsworth Hall, 611 North Pleasant Street Amherst Massachusetts 01003 USA
- Faculty of Arts, Business and Law; Tropical Forests and People Research Centre; University of the Sunshine Coast; 90 Sippy Downs Drive Sippy Downs Queensland 4556 Australia
| | - Martha L. Enriquez
- Department of Environmental Science; University of Girona; Montilivi Campus s/n 17071 Girona Spain
| | - Tom M. Fayle
- Institute of Entomology; Biology Centre of Academy of Sciences Czech Republic and Faculty of Science; University of South Bohemia; Branišovská 31 České Budějovice 370 05 Czech Republic
- Forest Ecology and Conservation Group; Imperial College London; Silwood Park Campus, Buckhurst Road Ascot SL5 7PY United Kingdom
| | - Donald H. Feener
- Department of Biology; University of Utah; Salt Lake City Utah 84112 USA
| | - Brian L. Fisher
- Entomology; California Academy of Sciences; San Francisco California USA
| | - Robert N. Fisher
- Western Ecological Research Center; U.S. Geological Survey; San Diego Field Station 4165 Spruance Road, Suite 200 San Diego California 92101 USA
| | - Matthew C. Fitzpatrick
- Appalachian Laboratory; University of Maryland Centre for Environmental Science; Frostburg Maryland 21532 USA
| | - Crisanto Gómez
- Department of Environmental Science; University of Girona; Montilivi Campus s/n 17071 Girona Spain
| | | | - Aaron Gove
- Astron Environmental Services; Perth Western Australia Australia
- Department of Environment and Agriculture; Curtin University; G.P.O. Box U1987 Perth Western Australia 6845 Australia
| | - Donato A. Grasso
- Department of Life Sciences; University of Parma; Parco Area delle Scienze 11/A Parma 43124 Italy
| | - Sarah Groc
- Instituto de Biologia; Universidade Federal de Uberlândia (UFU) Rua Ceara; Uberlândia Minas Gerais 38400-902 Brazil
| | - Benoit Guenard
- School of Biological Sciences; The University of Hong Kong; Pok Fu Lam Road Hong Kong China
| | - Nihara Gunawardene
- Department of Environment and Agriculture; Curtin University; G.P.O. Box U1987 Perth Western Australia 6845 Australia
| | - Brian Heterick
- Department of Environment and Agriculture; Curtin University; G.P.O. Box U1987 Perth Western Australia 6845 Australia
| | - Benjamin Hoffmann
- CSIRO Ecosystem Sciences, Tropical Ecosystems Research Centre; PMB 44 Winnellie Northern Territory 0822 Australia
| | - Milan Janda
- Institute of Entomology; Biology Centre of Academy of Sciences Czech Republic and Faculty of Science; University of South Bohemia; Branišovská 31 České Budějovice 370 05 Czech Republic
- Department of Biology; University of Guanajuato; Noria Alta sn. Guanajuato Mexico
| | - Clinton Jenkins
- IPÊ-Instituto de Pesquisas Ecológicas; Nazaré Paulista São Paulo 12960-000 Brazil
| | - Michael Kaspari
- Department of Biology; University of Oklahoma; 730 Van Vleet Oval, Room 314 Norman Oklahoma 73019 USA
| | - Petr Klimes
- Institute of Entomology; Biology Centre of Academy of Sciences Czech Republic and Faculty of Science; University of South Bohemia; Branišovská 31 České Budějovice 370 05 Czech Republic
- New Guinea Binatang Research Center; P.O. Box 604 Madang Papua New Guinea
| | - Lori Lach
- Centre for Tropical Biology and Climate Change; School of Marine and Tropical Biology; James Cook University; P.O. Box 6811 Cairns Queensland 4870 Australia
| | | | - John Lattke
- Departamento de Zoologia; Universidade Federal do Paraná; Caixa Postal 19020 81531-980 Curitiba Paraná Brazil
| | - Maurice Leponce
- Section of Biological Evaluation; Royal Belgian Institute of Natural Sciences; Rue Vautier, 29 Brussels 1000 Belgium
| | | | - John Longino
- Department of Biology; University of Utah; Salt Lake City Utah 84112 USA
| | - Andrea Lucky
- Entomology and Nematology Department; University of Florida; 970 Natural Area Drive Gainesville Florida 32611 USA
| | - Sarah H. Luke
- School of Biological Sciences; University of East Anglia; Norwich NR4 7TJ United Kingdom
- Department of Zoology; University of Cambridge; Downing Street Cambridge CB2 3EJ United Kingdom
| | - Jonathan Majer
- Department of Environment and Agriculture; Curtin University; G.P.O. Box U1987 Perth Western Australia 6845 Australia
- School of Plant Biology; The University of Western Australia; 35 Stirling Highway Crawley Western Australia 6009 Australia
| | - Terrence P. McGlynn
- Depatment of Biology; California State University Dominguez Hills; 1000 East Victoria Street Carson California 90747 USA
- Department of Entomology; Natural History Museum of Los Angeles County; Los Angeles California USA
| | - Sean Menke
- Department of Biology; Lake Forest College; 555 North Sheridan Road Lake Forest Illinois 60045 USA
| | - Dirk Mezger
- Division of Insects; Department of Zoology; Moreau Lab; Field Museum of Natural History; 1400 South Lake Shore Drive Chicago Illinois 60605 USA
| | - Alessandra Mori
- Department of Life Sciences; University of Parma; Parco Area delle Scienze 11/A Parma 43124 Italy
| | - Jimmy Moses
- Institute of Entomology; Biology Centre of Academy of Sciences Czech Republic and Faculty of Science; University of South Bohemia; Branišovská 31 České Budějovice 370 05 Czech Republic
- New Guinea Binatang Research Center; P.O. Box 604 Madang Papua New Guinea
| | - Thinandavha Caswell Munyai
- School of Life Sciences; College of Agriculture Engineering and Science; University of KwaZulu-Natal; Pietermaritzburg 3209 South Africa
| | - Renata Pacheco
- Instituto de Biologia; Universidade Federal de Uberlândia (UFU) Rua Ceara; Uberlândia Minas Gerais 38400-902 Brazil
| | - Omid Paknia
- Institute of Animal Ecology and Cell Biology; TiHo Hannover; Bünteweg 17d Hannover 30559 Germany
| | | | - Martin Pfeiffer
- Department of Ecology; National University of Mongolia; Baga Toiruu 47 P.O. Box 377 Ulaanbaatar 210646 Mongolia
| | - Stacy M. Philpott
- Environmental Studies Department; University of California; 1156 High Street Santa Cruz California 95060 USA
| | - Julian Resasco
- The Department of Ecology and Evolutionary Biology; University of Colorado; UCB 334 Boulder Colorado 80309 USA
| | - Javier Retana
- Universitat Autònoma Barcelona; Cerdanyola del Vallès 08193 Spain
| | - Rogerio R. Silva
- Coordenação de Ciências da Terra e Ecologia; Museu Paraense Emílio Goeldi; Belém Pará Brazil
| | - Magdalena D. Sorger
- Department of Applied Ecology; North Carolina State University; Raleigh North Carolina 27695 USA
| | - Jorge Souza
- Coordenação de Biodiversidade; National Institute of Amazonian Research; Manaus Amazonas Brazil
| | - Andrew Suarez
- Department of Entomology; University of Illinois, Urbana-Champaign; Urbana Illinois 61801 USA
| | - Melanie Tista
- Department of Tropical Ecology and Animal Biodiversity; University of Vienna; Rennweg 14 Vienna 1030 Austria
| | - Heraldo L. Vasconcelos
- Instituto de Biologia; Universidade Federal de Uberlândia (UFU) Rua Ceara; Uberlândia Minas Gerais 38400-902 Brazil
| | - Merav Vonshak
- Department of Biology; Stanford University; Stanford California 94305 USA
| | - Michael D. Weiser
- Department of Biology; University of Oklahoma; 730 Van Vleet Oval, Room 314 Norman Oklahoma 73019 USA
| | - Michelle Yates
- Centre for Behavioural and Physiological Ecology, Zoology; University of New England; Armidale New South Wales Australia
| | - Catherine L. Parr
- Department of Earth, Ocean and Ecological Sciences; University of Liverpool; Liverpool L69 3GP United Kingdom
| |
Collapse
|
43
|
Mori A, Ueda K, Lee P, Oda H, Ishioka K, Sako T. Influence of various carbohydrate sources on postprandial glucose, insulin and NEFA concentrations in obese cats. Pol J Vet Sci 2017; 19:387-91. [PMID: 27487514 DOI: 10.1515/pjvs-2016-0048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Carbohydrate is an important source of energy, which can significantly affect postprandial blood glucose and insulin levels in cats. In healthy animals, this is not a big concern; however, in obese and diabetic animals, this is an important detail. In the present study, the impact of four different carbohydrate sources (glucose, maltose, corn starch, and trehalose) on short-term post-prandial serum glucose, insulin, and non-esterified fatty acid (NEFA) concentrations was investigated with four obese cats. Each of the carbohydrate sources was added to a commercial wet food diet for feeding the animals. A significant difference was observed in postprandial glucose, insulin, and NEFA area under the curve (AUC) values between each carbohydrate source in obese cats. Furthermore, glucose and maltose induced the highest postprandial glucose and insulin AUC values, whereas trehalose induced the lowest postprandial glucose and insulin AUC value amongst all carbohydrate sources, respectively, in obese cats. However, trehalose has a higher risk of inducing side effects, such as diarrhea, as compared to other carbohydrate sources. As such, different carbohydrate sources appear to have a very significant impact on post-prandial glycemia and subsequent insulin requirement levels in obese cats. These results might be useful when selecting a prescription diet for obese or diabetic cats. In addition, maltose appears to be capable of inducing experimentally evoked postprandial hyperglycemia in obese cats, which may serve as a good tool for use to check the impact and effectiveness of newly developed oral hypoglycemic drugs or supplements for cats in future experiments.
Collapse
|
44
|
Kadono K, Uchida Y, Hirao H, Miyauchi T, Watanabe T, Iida T, Ueda S, Kanazawa A, Mori A, Okajima H, Terajima H, Uemoto S. Thrombomodulin Attenuates Inflammatory Damage Due to Liver Ischemia and Reperfusion Injury in Mice in Toll-Like Receptor 4-Dependent Manner. Am J Transplant 2017; 17:69-80. [PMID: 27467205 DOI: 10.1111/ajt.13991] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 07/18/2016] [Accepted: 07/20/2016] [Indexed: 01/25/2023]
Abstract
Liver ischemia reperfusion injury (IRI) is an important problem in liver transplantation. Thrombomodulin (TM), an effective drug for disseminated intravascular coagulation, is also known to exhibit an anti-inflammatory effect through binding to the high-mobility group box 1 protein (HMGB-1) known as a proinflammatory mediator. We examined the effect of recombinant human TM (rTM) on a partial warm hepatic IRI model in wild-type (WT) and toll-like receptor 4 (TLR-4) KO mice focusing on the HMGB-1/TLR-4 axis. As in vitro experiments, peritoneal macrophages were stimulated with recombinant HMGB-1 protein. The rTM showed a protective effect on liver IRI. The rTM diminished the downstream signals of TLR-4 and also HMGB-1 expression in liver cells, as well as release of HMGB-1 from the liver. Interestingly, neither rTM treatment in vivo nor HMGB-1 treatment in vitro showed any effect on TLR-4 KO mice. Parallel in vitro studies have confirmed that rTM interfered with the interaction between HMGB-1 and TLR-4. Furthermore, the recombinant N-terminal lectin-like domain 1 (D1) subunit of TM (rTMD1) also ameliorated liver IRI to the same extent as whole rTM. Not only rTM but also rTMD1 might be a novel and useful medicine for liver transplantation. This is the first report clarifying that rTM ameliorates inflammation such as IRI in a TLR-4 pathway-dependent manner.
Collapse
Affiliation(s)
- K Kadono
- Division of Hepato-Pancreato-Biliary Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.,Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka, Japan
| | - Y Uchida
- Division of Hepato-Pancreato-Biliary Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.,Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka, Japan
| | - H Hirao
- Division of Hepato-Pancreato-Biliary Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.,Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka, Japan
| | - T Miyauchi
- Division of Hepato-Pancreato-Biliary Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.,Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka, Japan
| | - T Watanabe
- Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - T Iida
- Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka, Japan
| | - S Ueda
- Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka, Japan
| | - A Kanazawa
- Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka, Japan
| | - A Mori
- Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka, Japan
| | - H Okajima
- Division of Hepato-Pancreato-Biliary Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - H Terajima
- Division of Hepato-Pancreato-Biliary Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.,Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka, Japan
| | - S Uemoto
- Division of Hepato-Pancreato-Biliary Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
45
|
Takamatsu N, Sogawa K, Nodera H, Hashiguchi S, Osaki Y, Saito M, Mori A, Izumi Y, Kaji R. Preferential changes of skeletal muscle echogenicity in myotonic dystrophy type 1. Eur J Neurol 2016; 24:366-373. [PMID: 27933692 DOI: 10.1111/ene.13212] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Accepted: 10/25/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND PURPOSE In myotonic dystrophy type 1 (DM1), weakness of distal limb muscles affects quality of life. Non-invasive evaluation of muscular involvement by muscle sonography could be useful for characterizing muscle-specific involvement. METHODS Sonography of the lower leg and forearm was performed in 19 patients with DM1 and 10 control subjects. The mean echo intensities (EIs) of seven limb muscles were obtained by computer-assisted histogram analysis and compared within DM1 according to the overall clinical severity. RESULTS The EIs of the muscles were significantly higher in DM1 than in the controls (P < 0.01), except for the soleus (P = 0.4). Comparison of adjacent muscles showed the following: (i) greater EIs in flexor digitorum profundus than flexor carpi ulnaris (P < 0.01) and flexor digitorum superficialis (P = 0.02), and (ii) greater EIs in the medial head of the gastrocnemius than the soleus (P < 0.00001). In a subgroup analysis of DM1 according to the modified Rankin Scale (mRS), the more severe subgroup (mRS = 4-5) had lower mean EIs than the less severe subgroup (mRS from 1-3) (P = 0.01) in the flexor digitorum superficialis but not in other muscles. CONCLUSIONS Preferential high echogenicity in the medial gastrocnemius and deep finger flexors is suggestive of DM1. Muscle echogenicity is not generally related to functional dysfunction in DM1.
Collapse
Affiliation(s)
- N Takamatsu
- Department of Neurology, Tokushima University, Tokushima, Japan
| | - K Sogawa
- Faculty of Medicine - Student Laboratory, Tokushima University, Tokushima, Japan
| | - H Nodera
- Department of Neurology, Tokushima University, Tokushima, Japan
| | - S Hashiguchi
- Department of Neurology, Tokushima Hospital, Tokushima, Japan
| | - Y Osaki
- Department of Neurology, Tokushima University, Tokushima, Japan.,Department of Neurology, Tokushima Hospital, Tokushima, Japan
| | - M Saito
- Department of Internal Medicine, Tokushima Hospital, Tokushima, Japan
| | - A Mori
- Department of Neurology, Tokushima University, Tokushima, Japan
| | - Y Izumi
- Department of Neurology, Tokushima University, Tokushima, Japan
| | - R Kaji
- Department of Neurology, Tokushima University, Tokushima, Japan
| |
Collapse
|
46
|
Im SA, Mukai H, Park I, Masuda N, Shimizu C, Kim S, Im YH, Ohtani S, Bartlett C, Lu D, Mori A, Gauthier E, Finn R, Toi M. 116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER +)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw577] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Mori A, Oda H, Onozawa E, Shono S, Takahashi T, Yamashita S, Fujimoto H, Sako T. Evaluation of portable blood glucose meters using canine and feline pooled blood samples. Pol J Vet Sci 2016; 19:707-713. [PMID: 28092618 DOI: 10.1515/pjvs-2016-0089] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
This study evaluated the accuracy and reproducibility of a human portable blood glucose meter (PBGM) for canine and feline whole blood. Reference plasma glucose values (RPGV) were concurrently measured using glucose oxidation methods. Fifteen healthy dogs and 6 healthy cats were used for blood sampling. Blood glucose concentrations and hematocrits were adjusted using pooled blood samples for our targeted values. A positive correlation between the PBGM and RPGV was found for both dogs (y = 0.877, x = -24.38, r = 0.9982, n = 73) and cats (y = 1.048, x = -27.06, r = 0.9984, n = 69). Acceptable results were obtained in error grid analysis between PBGM and RPGV in both dogs and cats; 100% of these results were within zones A and B. Following ISO recommendations, a PBGM is considered accurate if 95% of the measurements are within ± 15 mg/dl of the RPGV when the glucose concentration is <100 mg/dl and within ±15% when it is ≥100 mg/dl; however, small numbers of samples were observed inside the acceptable limits for both dogs (11%, 8 of 73 dogs) and cats (39%, 27 of 69 cats). Blood samples with high hematocrits induced lower whole blood glucose values measured by the PBGM than RPGV under hypoglycemic, normoglycemic, and hyperglycemic conditions in both dogs and cats. Therefore, this device is not clinically useful in dogs and cats. New PBGMs which automatically compensate for the hematocrit should be developed in veterinary practice.
Collapse
|
48
|
Rugo H, Dieras V, Gelmon K, Finn R, Slamon D, Miguel M, Neven P, Ettl J, Shparyk Y, Mori A, Lu D, Bhattacharyya H, Bartlett C, Iyer S, Johnston S, Harbeck N. Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.04] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Watai K, Sekiya K, Nakamura Y, Hamada Y, Tomita Y, Mistui C, Hayashi H, Kamide Y, Tsuburai T, Fukutomi Y, Mori A, Taniguchi M. Even short-term smoking can cause lower lung function and bronchial hyperresponsiveness in young adult-onset patients with asthma. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.07.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Mori A, Jono T, Takeuchi H, Ding L, Silva A, Mahaulpatha D, Tang Y. Morphology of the nucho‐dorsal glands and related defensive displays in three species of Asian natricine snakes. J Zool (1987) 2016. [DOI: 10.1111/jzo.12357] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A. Mori
- Department of Zoology Graduate School of Science Kyoto University Sakyo Kyoto Japan
| | - T. Jono
- Chengdu Institute of Biology Chinese Academy of Sciences Chengdu Sichuan China
| | - H. Takeuchi
- Department of Zoology Graduate School of Science Kyoto University Sakyo Kyoto Japan
- Seto Marine Biological Laboratory Field Science Education and Research Center Kyoto University Shirahama Wakayama Japan
| | - L. Ding
- Chengdu Institute of Biology Chinese Academy of Sciences Chengdu Sichuan China
| | | | | | - Y. Tang
- Chengdu Institute of Biology Chinese Academy of Sciences Chengdu Sichuan China
| |
Collapse
|